Hims & Hers Health Inc., a telehealth company based in San Francisco, is facing securities class action lawsuits following allegations that the company promoted and sold illegitimate versions of the weight-loss drug Wegovy. The lawsuits claim that Hims & Hers' actions endangered patients and posed a risk to its recently announced partnership with pharmaceutical giant Novo Nordisk. This partnership, centered on offering FDA-approved Wegovy through the Hims & Hers platform, was abruptly terminated by Novo Nordisk on June 23, 2025. The termination followed revelations of Hims & Hers' deceptive promotion practices and sales of knockoff products sourced from unregulated foreign suppliers. As a result of this news, Hims & Hers' stock price plummeted by 34.6%, highlighting the significant impact of the allegations on the company's market value. Investors who acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, are encouraged to engage in the class action process before the lead plaintiff motion deadline on August 25, 2025.